Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

36.70 USD -0.05 (-0.14%)
Official Closing Price Updated: 7:59 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2
Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2... 
From Business Wire News Releases
Thinking about trading options or stock in Pfizer, Apple, Anheuser Busch, Carnival Corp, or Tesla?
InvestorsObserver issues critical PriceWatch Alerts for PFE, AAPL, BUD, CCL, and TSLA. 
From PR Newswire
Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers at SITC 2020
Regulatory News: 
From Business Wire News Releases
Thinking about buying stock in American Airlines, Carnival Corp, Pfizer, Aptevo Therapeutics, or Aurora Cannabis?
InvestorsObserver issues critical PriceWatch Alerts for AAL, CCL, PFE, APVO, and ACB. 
From PR Newswire
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
From GlobeNewswire News Releases
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in... 
From Business Wire News Releases
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
From GlobeNewswire News Releases
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
ViiV HC announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women 
From Business Wire News Releases
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)
Pfizer Inc. (NYSE: PFE) announced today positive results from a Phase 3 investigational study evaluating the safety and efficacy of tofacitinib in adults with active ankylosing spondylitis (AS).... 
From Business Wire News Releases
XTANDI® (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Enzalutamide is now NMPA-approved for both non-metastatic and metastatic castration-resistant prostate cancer 
From PR Newswire
Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc. As... 
From Business Wire News Releases
Covid-19 Resurgence Leading to Increasing Demand For Automated UV-C Light-Based Surface Disinfection Systems
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Covid-19 Resurgence Leading to Increasing Demand For Automated UV-C Light-Based Surface Disinfection Systems
Financialnewsmedia.com News Commentary 
From PR Newswire
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen... 
From PR Newswire
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual) – Friday, November 13, 2020
Join us as we discuss today’s pressing healthcare issues. 
From Business Wire News Releases
Vaccine Development Holdups Reinforce the Need for Interim Solutions
FinancialBuzz.com News Commentary 
From PR Newswire
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
Pfizer Announces Record Date for the Proposed Transaction 
From PR Newswire
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of the... 
From Business Wire News Releases
Thinking about trading options or stock in AT&T, Pfizer, Royal Caribbean Cruises, American Airlines, or Qualcomm?
InvestorsObserver issues critical PriceWatch Alerts for T, PFE, RCL, AAL, and QCOM. 
From PR Newswire
Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Why Gastrointestinal (GI) Cancer Drugs Are Expected to See Significant Growth Over Next Few Years
Financialnewsmedia.com News Commentary 
From PR Newswire
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Priority Review designation to the company’s New Drug Application (NDA) for... 
From Business Wire News Releases
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2020 and updated and tightened certain components of Total Company(3) 2020 financial guidance, which continues to reflect actual and... 
From Business Wire News Releases
Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers
Regulatory News: 
From Business Wire News Releases
Thinking about buying stock in Pfizer, Delta Air Lines, Norwegian Cruise Line, CTI BioPharma, or Honeywell?
InvestorsObserver issues critical PriceWatch Alerts for PFE, DAL, NCLH, CTIC, and HON. 
From PR Newswire
Diagnostic Testing Capabilities Improve in the Face of Global Turmoil
FinancialBuzz.com News Commentary 
From PR Newswire
Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020
Pfizer Inc. (NYSE:PFE) today announced the full analysis from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine... 
From Business Wire News Releases
Analgesics Market : Facts, Figures and Analytical Insights 2020 : Bayer Healthcare, Pfizer, Sanofi, Johnson & Johnson and Novartis AG
Harrisburg, NC -- (SBWIRE) -- 10/20/2020 -- The Analgesics Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry... 
From SBWire - Latest Press Releases
Thinking about trading options or stock in Pfizer, Exxon Mobil, Verizon, Intel Corp, or Roku?
InvestorsObserver issues critical PriceWatch Alerts for PFE, XOM, VZ, INTC, and ROKU. 
From PR Newswire
Psychedelics Could Become the Next Health and Wellness Trend
FN Media Group Presents Microsmallcap.com Market Commentary 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.